Frankfurt - Delayed Quote EUR

aTyr Pharma, Inc. (471A.F)

3.2800

0.0000

(0.00%)

At close: January 29 at 8:10:46 AM GMT+1

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025 Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on real-world evidence SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of

GlobeNewswire 16 hours ago

ATYR
Several Insiders Invested In aTyr Pharma Flagging Positive News

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. 19 days ago

ATYR
Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and an anticipated annual earnings growth of 15%. In this dynamic environment, identifying high-growth tech stocks involves assessing their potential to capitalize on technological advancements and market trends while aligning with robust growth forecasts.

Simply Wall St. last month

VNDA

ATYR

KNSA
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%

Key Insights Significantly high institutional ownership implies aTyr Pharma's stock price is sensitive to their trading...

Simply Wall St. last month

ATYR
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA. Details of the presentation app

GlobeNewswire last month

ATYR
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company’s Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). “We are excited

GlobeNewswire last month

ATYR
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Independent data and safety monitoring board (DSMB) review includes all 268 patients who have been enrolled in the study and recommends continuation of study without any modifications.SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the outcome of a third, pre-planned inte

GlobeNewswire last month

ATYR
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in models of lung and kidney fibrosis.SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters

GlobeNewswire last month

ATYR
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution, which is scheduled to take place December 8

GlobeNewswire 2 months ago

ATYR
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Respiratory Journal demonstrated statistically significant difference in time-to-first relapse for corticosteroid use and improvement in corticosteroid relapse rate for efzofitimod. SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged i

GlobeNewswire 2 months ago

ATYR
aTyr Pharma to Present at Upcoming Investor Conferences

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at several upcoming investor conferences scheduled to take place in November and December 2024. Details of the conferences appear below: Conference: Stifel Healthcare ConferenceDate: Monday, November 18, 2024 Time: 3:35p

GlobeNewswire 2 months ago

ATYR
High Growth Tech Stocks to Watch in October 2024

Over the last 7 days, the United States market has dropped 1.0%, but it has risen by 38% over the past year, with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on future opportunities.

Simply Wall St. 3 months ago

EEX

ATYR

SLP
aTyr Pharma to Present at the LD Micro Main Event XVII in October

San Diego, California--(Newsfile Corp. - October 14, 2024) - aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 17th Annual LD Micro Main Event, which is scheduled to take place October 28 – 30, 2024, in Los Angeles, CA.Details ...

Newsfile 3 months ago

ATYR
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company’s lead therapeutic candidate, efzofitimod, will be featured in the Best of CHEST Journals session at the CHEST 2024 Annual Meeting, which is scheduled to take place October 6 – 9, 2024, in Boston, MA. “We ar

GlobeNewswire 3 months ago

ATYR
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups. 54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compared to 7.7% in the therapeutic group. SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage bi

GlobeNewswire 3 months ago

ATYR
aTyr Pharma to Participate in September Investor Conferences

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024. Details of the conferences appear below: Conference: Wells Fargo Healthcare ConferenceDate: Thursday, September 5, 2024 Location: Ev

GlobeNewswire 5 months ago

ATYR
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 months ago

ATYR
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicine

GlobeNewswire 5 months ago

ATYR
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Jayant Aphale, Ph.D., as Vice President, Technical Operations. Dr. Aphale will serve as a member of the Company’s executive leadership team, overseeing manufacturing activities at contract development and

GlobeNewswire 5 months ago

ATYR
aTyr Pharma Announces Research Study with Stanford Medicine

Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain cancer.SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research agreement with Stanford Medicine. Michael Lim, M.

GlobeNewswire 5 months ago

ATYR

Performance Overview

Return	471A.F	S&P 500
YTD	-7.34%	+2.24%
1-Year	+135.97%	+23.48%
3-Year	-30.51%	+36.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

aTyr Pharma, Inc. (471A.F)

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Several Insiders Invested In aTyr Pharma Flagging Positive News

Exploring Three High Growth Tech Stocks In The United States

aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57%

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

aTyr Pharma to Present at Upcoming Investor Conferences

High Growth Tech Stocks to Watch in October 2024

aTyr Pharma to Present at the LD Micro Main Event XVII in October

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

aTyr Pharma to Participate in September Investor Conferences

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

aTyr Pharma Announces Research Study with Stanford Medicine

Performance Overview